The global biopsy devices market revenue was around US$ 2.49 billion in 2022 and is estimated to reach US$ 4.50 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.8% during the forecast period from 2023 to 2031.
A biopsy is a procedure in which tissue from an organ is surgically removed to assess the existence or severity of a disease, typically cancerous and inflammatory disorders. It is typically performed by the radiologists, surgeons, and interventional cardiologists. Biopsies can be carried out on any organ using certain biopsy devices as a confirmatory test for celiac and cancer disease. The usage of each biopsy device varies depending on different type of organ under consideration.
Market Driving Factors
Increasing cancer incidence spurs the market growth. An increased prevalence of cancer in the population and the fact that it is the main cause of death in Canada and the US, respectively. For instance, according to the American Cancer Society, there are 1.9 million people received a cancer diagnosis, and 693,000 people died from the disease. In North America, prostate cancer is the illness that is most frequently diagnosed in males, but breast cancer remains the most common cancer in women. Lung cancer remains to be the leading cause of death in both genders.
Surging innovation and advancements benefit the market. The enhanced research and development efforts in the field of biopsy devices are expected to generate the potential for the market. Furthermore, the introduction of cutting-edge products like the Celero VAB device, Finesse Ultra Breast Biopsy System, and Vacora will accelerate the market growth.
Strict regulations for the use of biopsies hamper the market growth.
Regional Analysis
North America dominates the market in terms of the largest shares. This is due to the presence of well-established key participants in the region, innovative products like vacuum-assisted biopsy systems have a high market penetration rate, and rapidly increase market demand for disposable products. Furthermore, the inclination towards minimally invasive procedures, an increase in cancer incidence worldwide, and government initiatives for diagnosis in the region are the elements that propel the market growth.
Segmentation Insights
Product Type Insight
The biopsy guns segment dominated the market in terms of the largest shares. An increase in demand for these weapons to obtain samples from internal organs' soft tissues, like breasts, kidneys, and lungs, is predicted to support the market growth. Furthermore, the growing need for delicate and quick cell sample collection for biopsies is one of the primary factors promoting the segment's expansion.
Application Insight
The breast biopsy segment dominated the market in terms of shares and is predicted to maintain its dominance over the projection period. This is due to the number of incidences of breast cancer has increased over time and is expected to continue in the upcoming years. Currently, breast cancer can be detected swiftly and efficiently utilizing modern biopsy tools.
Guidance Technique Insight
Ultrasound-guided biopsy segment is predicted to dominate the market. This is due to the rising prevalence of this technique for cancer diagnosis in diagnostic laboratories, as well as its numerous benefits and wide range of applications. These benefits include high efficiency, high throughput, accuracy, and low invasiveness, all of which are expected to drive the segment's growth.
End User Insight
The hospitals & clinics segment dominated the market in terms of the largest shares. Due to the widespread availability of advanced medical equipment and reimbursement regulations. The National Average Medicare rate for breast biopsy procedures in hospitals was around US$1,400 which included the implantation of a breast localization device.
Prominent Companies
Segmentation Outline
The global biopsy devices market segmentation focuses on Product Type, Application, Guidance Technique, End User, and Region.
By Product Type
By Application
By Guidance Technique
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL BIOPSY DEVICES MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: BIOPSY DEVICES MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL BIOPSY DEVICES MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL BIOPSY DEVICES MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 BIOPSY GUNS
5.3 BIOPSY GUIDANCE SYSTEM
5.4 BIOPSY NEEDLES
5.4.1 VACUUM-ASSISTED BIOPSY (VAB) DEVICES
5.4.2 FINE NEEDLE ASPIRATION BIOPSY (FNAB) DEVICES
5.4.3 CORE NEEDLE BIOPSY (CNB) DEVICES
5.5 BIOPSY FORCEPS
5.6 LOCALIZATION WIRES
5.7 OTHERS
6 GLOBAL BIOPSY DEVICES MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 BREAST BIOPSY
6.3 PROSTATE BIOPSY
6.4 LIVER BIOPSY
6.5 LUNG BIOPSY
6.6 GYNECOLOGICAL BIOPSY
6.7 OTHERS
7 GLOBAL BIOPSY DEVICES MARKET, BY GUIDANCE TECHNIQUE
7.1 OVERVIEW
7.2 ULTRASOUND-GUIDED BIOPSY
7.3 STEREOTACTIC GUIDED BIOPSY
7.4 MRI-GUIDED BIOPSY
7.5 CT GUIDED BIOPSY
7.6 OTHERS
8 GLOBAL BIOPSY DEVICES MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS & CLINICS
8.3 DIAGNOSTIC & IMAGING CENTERS
8.4 ACADEMIC & RESEARCH INSTITUTES
8.5 OTHERS
9 GLOBAL BIOPSY DEVICES MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3.1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL BIOPSY DEVICES MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
10.4 COMPETITIVE DASHBOARD
10.5 PRODUCT MAPPING
10.6 TOP PLAYER POSITIONING, 2022
10.7 COMPETITIVE HEATMAP
10.8 TOP WINNING STRATEGIES
11 COMPANY PROFILES
11.1 ARGON MEDICAL DEVICES
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.2 COOK MEDICAL
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.3 CONMED CORPORATION
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.4 OLYMPUS CORPORATION
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.5 HOLOGIC, INC
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.6 CARDINAL HEALTH INC
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.7 INTEGRA LIFESCIENCES
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.8. MEDTRONIC PLC
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.9 MAMMOTOME
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.10 INRAD
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.11 TRIVITRON HEALTHCARE
11.11.1 OVERVIEW
11.11.2 FINANCIAL PERFORMANCE
11.11.3 PRODUCT OUTLOOK
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved